Pharmaceuticals

Details Pharmaceuticals Pharmaceuticals

2006-05-16

2006-05-16

Tsang, Cecilia J. (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carboxylic acids and salts thereof

C560S121000, C560S122000

Reexamination Certificate

active

07045653

ABSTRACT:
The invention relates to NEP inhibitors for treating cardiovascular disorders. Preferred NEP inhibitors are compounds of formula (I) wherein R1is C1–C6alkyl, C1–C6alkoxyC1–C3alkyl or C1–C6alkoxyC1–C6alkoxyC1–C3alkyl; R2is hydrogen or C1–C6alkyl; L is a three atom linkage selected from —CH2—X—CH2— and —CH2—CH2—X— where the right hand side of the linkage is attached to R3and where X is oxygen, sulfur or methylene; R3is phenyl or aromatic heterocyclyl, either of which may be independently substituted by one or more groups selected from: C1–C6alkyl, halo, haloC1–C6alkyl, C1–C6alkoxy, haloC1–C6alkoxy, C1–C6alkylthio, haloC1–C6alkylthio and nitrile; and R4and R5are either both hydrogen, or one of R4and R5is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen.

REFERENCES:
patent: 4722810 (1988-02-01), Delaney et al.
patent: 4929641 (1990-05-01), Haslanger et al.
patent: 5208236 (1993-05-01), Neustadt
patent: 5244889 (1993-09-01), MacPherson et al.
patent: 5389610 (1995-02-01), Neustadt et al.
patent: 5508272 (1996-04-01), Robl
patent: 5552397 (1996-09-01), Karanewsky et al.
patent: 5672599 (1997-09-01), Robl
patent: 5677297 (1997-10-01), Waldeck et al.
patent: 5723457 (1998-03-01), Karanewsky et al.
patent: 5723602 (1998-03-01), Karanewsky et al.
patent: 5783573 (1998-07-01), Rozsa et al.
patent: 5859239 (1999-01-01), Karanewsky et al.
patent: 5891912 (1999-04-01), Kawashima et al.
patent: 5968980 (1999-10-01), Kawashima et al.
patent: 0136883 (1985-04-01), None
patent: 0254032 (1988-01-01), None
patent: 0358398 (1990-03-01), None
patent: 0274234 (1991-09-01), None
patent: 0509442 (1992-10-01), None
patent: 0519738 (1992-12-01), None
patent: 0544620 (1993-06-01), None
patent: 0599444 (1994-06-01), None
patent: 0629627 (1994-12-01), None
patent: 0640594 (1995-03-01), None
patent: 0655461 (1995-05-01), None
patent: 0690070 (1996-01-01), None
patent: 0738711 (1996-10-01), None
patent: 0798291 (2002-09-01), None
patent: (1993)592948 (1993-04-01), None
patent: (1995)7157459 (1995-06-01), None
patent: (1996)841015 (1996-02-01), None
patent: (1996)8245609 (1996-09-01), None
patent: WO 91/07386 (1991-05-01), None
patent: WO 91/13054 (1991-09-01), None
patent: WO 93/09101 (1993-05-01), None
patent: WO 94/15908 (1994-07-01), None
patent: WO 91/08195 (1994-11-01), None
patent: WO 91/09840 (1995-05-01), None
patent: WO 97/24342 (1997-07-01), None
patent: WO 02/03995 (2002-01-01), None
patent: WO 2004/056750 (2004-07-01), None
Biochem. Biophys. Res. Commun. vol., 164, p. 58, 1989.
Biochem. Soc. Trans. vol., 21(3), p. 678, 1993.
Bioorg. Med. Chem. Letts. vol., 4(22), p. 2715, 1994.
Bioorg. Med. Chem. Letts. vol., 6(1), p. 65, 1996.
Bioorg. Med. Chem. Letts vol., 11(3), p. 375, 2001.
Bioorg. Med. Chem. Letts vol., 12, p. 3059, 2002.
Cardiovasc. Drug Rev. vol., 9(3), p. 285, 1991.
Cardiovasc. Drug Rev. vol., 12(4), p. 271, 1994.
Cardiovasc. Drug Rev. vol., 14(2), p. 166, 1996.
Chemtracts vol., 10(11), p. 804, 1997.
Clin. Exp. Pharmacol. Physiol. vol., 22(1), p. 63, 1995.
Curr. Opin. Inves. Drugs vol., 2(11), p. 1175, 1993.
Current Pharm. Design vol., 2(5), p. 443, 1996.
Exp. Opin. Ther. Patents vol., 6(11), p. 1147, 1996.
Gen. Pharmacol. vol., 27(4), p. 581, 1996.
Handbook Exp. Pharmacol. vol., 104(1), p. 547, 1993.
J. Med. Chem. vol., 36(1), p. 87, 1993.
J. Med. Chem. vol., 36(16), p. 2420, 1993.
J. Med. Chem vol., 36(24) p. 3821, 1993.
J. Med. Chem vol., 38(26), p. 5023, 1995.
Pathol. Biol. vol., 46(3), p. 191, 1998.
Perspect. Med. Chem. p. 45, 1993.
Pharmacol. Rev. vol., 45(1), p. 87, 1993.
TiPS vol., 11, p. 245, 1990.
Zinc Metalloproteases Health Dis. p. 105, 1996.
Fournie-Zaluski MC, Gonzalez W, Turcaud S, Pham I, Roques BP, Michel JB, Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proceedings of the National Academy of Sciences of the United States of America. 91(9):4072-6, Apr. 26, 1994.
Fournie-Zaluski MC, Corie P, Turcaud S, Rousselet N, Gonzalez W, Barbe B, Pham I, Jullian N. Michel JB, Roques BP, New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension, Journal of Medicinal Chemistry, 37(8):1070-83, Apr. 15, 1994.

Affiliated with

Also associated with

Rating

Pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceuticals will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3524984